Key terms
About LEXX
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LEXX news
Apr 16
3:07pm ET
Lexaria Advances with New GLP-1 Drug Study
Apr 16
9:30am ET
Lexaria Bioscience receives ethics review board approval for GLP-1 study
Apr 02
12:37pm ET
Lexaria Secures New Patents, Bolsters Pharma Tech
Mar 21
1:07pm ET
Lexaria Bioscience Showcases Drug Delivery Breakthrough
Mar 14
12:37pm ET
Lexaria Bioscience Welcomes New CFO
Mar 12
5:11pm ET
Lexaria Bioscience files to sell 1.61M shares of common stock for holders
Mar 07
1:37pm ET
Lexaria Bioscience Advances Oral Diabetes Treatment
Mar 07
9:11am ET
Lexaria Bioscience hires CRO for GLP-1 human pilot study
Mar 05
12:37pm ET
Lexaria Tests New Diabetes and Weight Loss Formulations
Mar 05
11:33am ET
Lexaria Bioscience price target raised to $12 from $3 at Maxim
Mar 04
12:37pm ET
Lexaria Advances Drug Delivery with Promising Study
Mar 04
9:20am ET
Lexaria Bioscience says DehydraTECH-CBD study resulted in weight loss in rodents
Mar 01
8:23am ET
Lexaria Bioscience announces FDA clearance of Phase 1b hypertension trial
Feb 15
8:07am ET
Lexaria Bioscience prices $3.6M registered direct offering at $2.31 per share
Jan 30
8:50am ET
Lexaria Bioscience submits IND application to FDA for DehydraTECH-CBD trial
Jan 24
8:54am ET
Lexaria Bioscience says ‘never been more confident’ in IP portfolio
Jan 22
3:01pm ET
Analysts Offer Insights on Healthcare Companies: Lexaria Bioscience (LEXX), Evolus (EOLS) and Inspire Medical Systems (INSP)
LEXX Financials
Key terms
Ad Feedback
LEXX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LEXX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range